Morgan Stanley Maintains Overweight on Bicara Therapeutics, Lowers Price Target to $30
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and lowers the price target from $41 to $30.
Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and lowers the price target from $41 to $30.